Navigation Links
Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
Date:6/9/2009

- SYNCHRONY Study Published in The Lancet Supports Cardio-Protective Potential of Aleglitazar -

NUTLEY, N.J., June 9 /PRNewswire/ -- Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This decision is supported by data from the Phase II SYNCHRONY study published today in The Lancet(1) and announced at the American Diabetes Association meeting in New Orleans. The Phase III program is anticipated to start in the second half of 2009.

SYNCHRONY, a placebo-controlled dose ranging study in type 2 diabetes patients, showed that aleglitazar had a balanced synergistic effect on both lipid and glucose control with a good safety and tolerability profile in patients with type 2 diabetes.

Cardiovascular disease is currently the leading cause of death among those with type 2 diabetes, accounting for half of all deaths.(2) Despite guidelines recommending that cardiovascular risk in this patient group should be reduced by controlling factors such as dyslipidemia, blood pressure, body weight and hyperglycemia,(3,4) the majority of patients still do not achieve their treatment goals leaving them vulnerable to both initial and residual cardiovascular events.(3,5) Significantly, one in ten patients with an acute myocardial infarction died within a year.(6)

"Roche is confident that aleglitazar has the potential to reduce cardiovascular morbidity and mortality in this high-risk patient group and is therefore committed to pursuing its rapid development," said Jean-Jacques Garaud, Global Head of Development Pharmaceuticals Division of Roche.

The focused Phase III outcomes trial will investigate whether once daily 150 micrograms aleglitazar reduces the incidence of cardiovascular mortality, non-f
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier
2. moksha8 Expands Alliance With Roche to Commercialize $200 Million of Products in Brazil and Mexico
3. Roches Pierson Honored as 2009 HBA Rising Star
4. Corporate Pandemic Preparedness Experts from Roche & PSEG to Advise Savvy Business Leaders May 15
5. Roche Women Honored as 2009 TWIN Awardees
6. Rochester Medical Reports Second Quarter Results
7. Sanofi-Aventis and Roche/Chugais Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
8. Roche Announces New Co-pay Program in Pennsylvania that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips
9. Roche Announces New Co-pay Program in Florida that Makes It Easier for Patients with Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips
10. Roche Announces New Co-Pay Program in California That Makes it Easier for Patients With Diabetes to Receive Savings on ACCU-CHEK(R) Blood Glucose Test Strips
11. Rochester Medical Announces Second Quarter 2009 Earnings Conference Call April 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... widespread across the United States, due in large to ... of clinical data that will become available for research ... experts in healthcare have become increasingly focused on clinical ... purpose of gleaning insights that have the potential to ... that is known as big data. ...
(Date:7/10/2014)... Adults with dyslexia are more likely to report that ... people who don,t have the learning disorder, according to ... to 10 percent of people, causes problems with reading ... with this condition said they suffered physical abuse during ... dyslexia. "Even after accounting for age, race, sex ...
(Date:7/10/2014)... News) -- Men who have a vasectomy may be ... study suggests. But the risk is comparatively small, ... the study said more research is needed to determine ... the study, Harvard researchers analyzed data from more than ... starting in 1986. During that time, 6,023 cases of ...
(Date:7/10/2014)... 2014In response to today,s announcement that the "Mississippi Baby," ... now been found to have detectable levels of the ... disappointment in this setback but remains hopeful that the ... remain undetectable for more than two years will continue ... ultimately develop a cure. , "Although we had ...
(Date:7/10/2014)... device developed at the Massachusetts General Hospital (MGH) Center ... can be cultured to establish cell lines for genetic ... issue of Science , an MGH research team ... genetic mutation over time and changing susceptibility to therapeutic ... the blood that represent those present in metastatic deposits, ...
Breaking Medicine News(10 mins):Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 2Health News:Cultured CTCs reveal genetic profile, potential drug susceptibility of breast cancer cells 3
... BALTIMORE, April 30 MDDCcommunity.com would like to announce ... local member company. Over the past few months Dynasplint(R) ... establishing more of a presence online. Their expansion includes ... Twitter account, all of which are intended to provide ...
... April 30 The Missouri House today amended ... funds to go to grants for maternity homes and pregnancy ... being considered by the Missouri Senate. , , ... homes and pregnancy resource centers are essential to helping pregnant ...
... The ,Help is Here Express, bus tour will be stopping ... 8th at various cities in order to help uninsured and ... for free or nearly free. With the state,s unemployment rate ... is ready to help state residents who face layoffs and ...
... YORK and NASSAU, The Bahamas, April 30 ... of Fincor (FINC) through a 1:1 share split. Prospero ... Technologies enlarges thru Fincor its portfolio with the new ... the WETTECH and Advanced Cavitation Technologies. Prospero ...
... are abandoned again! WEST PALM BEACH, Fla., April ... a civil rights and negligence lawsuit in New York ... Welfare Administration and four other agencies for failure to ... state-licensed foster parent.Identified in the filing only by their ...
... and psychological repercussions that impact quality of life and ... ability to remain employed. Compared to individuals with other ... have a more profound effect on a person,s ability ... of those with severe forms of arthritis were not ...
Cached Medicine News:Health News:Dynasplint Systems, Inc. Launches Two New Web Sites Plus Social Media Tools 2Health News:Partnership for Prescription Assistance Prepared to Help Kansan Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Kansan Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Kansan Workers Hurt by Recession 4Health News:Prospero Group (PRPG) and Fincor (FINC) Made a Share Transfer and Enter the Market with ACTRx a New Malaria and Dengue Fever Treatment 2Health News:Severely Abused Foster Children Sue New York City Child Welfare Agencies After their Failure to Help Them 2Health News:Women with arthritis more likely than men to stop working 2Health News:Women with arthritis more likely than men to stop working 3
(Date:7/10/2014)... -- Integrated Silicon Solution, Inc. (Nasdaq: ISSI ... solutions, today announced that it will host its earnings ... a.m. Pacific Time (10:00 a.m. Eastern Time) to discuss ... quarter ended June 30, 2014. To access ... a.m. Pacific time on July 24, 2014.  The participant ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
(Date:1/15/2014)... 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today announced ... 2013, compared to sales of $2,202,000 for the prior year ... quarter has also shown growth over the preceding quarter,s sales, ... this fiscal year. Markets that experienced sales increases over the ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... CITY, Feb. 28, 2011 Concentra, a subsidiary of ... the future of occupational and urgent care through a ... experiences for clients and patients. Recent customer loyalty ratings ... of top U.S. consumer companies as a leader in ...
... ISLAND, N.Y., Feb. 28, 2011  A 67-year-old man with ... wife after wandering outside in near-freezing temperatures thanks to the ... watch-like EmSeeQ® wearable locator device. Robert ... discovered him missing. He was located on Victory Boulevard, more ...
Cached Medicine Technology:Concentra is Writing a New Prescription on Health Care With Outstanding Service 2Concentra is Writing a New Prescription on Health Care With Outstanding Service 3Concentra is Writing a New Prescription on Health Care With Outstanding Service 4Concentra is Writing a New Prescription on Health Care With Outstanding Service 5Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 2Staten Island Man Now Safe at Home Thanks to EmSeeQ® Locator Device 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: